Intra-Arterial Insulin Will Probe Vascular Control in Obesity and Insulin Resistance
A University of Missouri-Columbia study is set to examine a deceptively basic question with wide metabolic implications: does insulin produce the same peripheral vascular response in people with obesity and insulin resistance as it does in normal-weight adults? The trial, Peripheral Vascular Effects of Insulin in Obesity (NCT07874945), is designed as an early phase 1, interventional, non-randomized study with parallel groups and open-label administration of intra-arterial human insulin. Its primary readout is forearm blood flow measured over a 5-minute resting average.
In obesity, the problem is not simply excess adiposity. Skeletal muscle may receive an inadequate microvascular response to insulin, and when capillary perfusion lags, glucose delivery to muscle fibers can fall behind metabolic need. The protocol’s central premise is that sympathetic nervous system overactivity may contribute to that malperfusion, creating a vascular bottleneck during hyperinsulinemia and impairing glucose uptake. In practical terms, the study is testing whether the vasculature itself is part of the insulin resistance phenotype rather than a passive bystander.
The design is tightly focused. Two cohorts are planned: healthy normal-weight adults and adults with obesity plus comorbid insulin resistance. Eligibility criteria define the groups clearly, with obesity requiring a body mass index between 30 and 45 kg/m2, central adiposity by waist circumference, and insulin resistance reflected by HOMA-IR of at least 2.5. Normal-weight controls must have a BMI between 18 and 25 kg/m2, lower waist circumference, and HOMA-IR below 2. The planned enrollment is 64 participants.
One sentence captures the clinical logic of the trial: if insulin cannot recruit blood flow to muscle, glucose disposal can suffer before any changes in laboratory markers become obvious.
The study’s exclusions help isolate the vascular physiology under investigation. Diabetes, polycystic ovarian syndrome, established cardiovascular disease, neurologic disease, uncontrolled hypertension, active cancer, current smoking or nicotine use, recent major weight change, anticoagulation therapy, and hypersensitivity to nitrates or lidocaine all remove confounders that could distort vascular reactivity or complicate arterial procedures. Pregnancy and breastfeeding are excluded as well. These criteria may appear broad, but they are doing important methodological work: they narrow the field to a metabolic phenotype in which forearm vascular responses can be interpreted with less noise from competing pathology.
The intervention itself is straightforward but biologically rich. Participants will receive human insulin administered intra-arterially. Local arterial delivery allows investigators to interrogate peripheral vascular effects directly rather than relying on systemic metabolic consequences alone. That matters because insulin has dual biology: it is a classical metabolic hormone, but it also exerts vascular actions through endothelial and sympathetic pathways that can alter blood flow to skeletal muscle. When those vascular actions are blunted, the downstream effect may be a mismatch between circulating hormone signal and tissue-level nutrient delivery.
Forearm blood flow is an elegant choice for a mechanistic study. It provides a window into resistance-vessel behavior in a controlled limb circulation, where local infusion and physiologic measurement can be linked more directly than in whole-body metabolic experiments. By comparing responses in obese insulin-resistant adults with those in normal-weight controls, the trial may help determine whether the vascular component of insulin resistance is exaggerated in obesity, absent in controls, or simply different in magnitude. Even without a clinical endpoint such as glucose tolerance or diabetes progression, a clean vascular signal would be informative because it would help map where insulin action fails first.
The exclusion of participants with cardiovascular disease also suggests the investigators want to avoid conflating obesity-related microvascular dysfunction with overt macrovascular disease. That is a sensible choice for an early physiology study, but it leaves an important boundary around interpretation: the findings will speak most directly to relatively younger or healthier adults with obesity and insulin resistance, not to the broader population with diabetes, established atherosclerosis, or long-standing vascular injury. The study will begin with estimated start in December 2026, with primary completion anticipated in June 2031 and final study completion in June 2032.
A second sentence worth sitting with: this is not a drug efficacy trial in the usual sense; it is a probe of mechanism.
Because the study is early phase 1 and open label, it is not built to settle therapeutic questions about long-term vascular outcomes or to support treatment claims. The real value lies upstream. If insulin fails to augment forearm perfusion in obesity and insulin resistance, the result would reinforce a model in which sympathetic activation and microvascular dysfunction help sustain impaired glucose handling. If the response is preserved, the field would need to look elsewhere for the dominant physiologic defect.
The record also notes that the study is a U.S. FDA-regulated drug product study and that individual participant data sharing remains undecided. No location data are listed yet, and no results have been posted. For now, the trial stands as a carefully constructed experiment in human vascular physiology, one that may clarify how obesity reshapes the insulin signal at the level of blood flow before metabolism is ever measured in earnest.